Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Lee, Catherine J.; Wang, Tao; Chen, Karen; Arora, Mukta; Brazauskas, Ruta; Spellman, Stephen R.; Kitko, Carrie; MacMillan, Margaret L.; Pidala, Joseph A.; Badawy, Sherif M.; Bhatt, Neel; Bhatt, Vijaya R.; DeFilipp, Zachariah; Diaz, Miguel A.; Farhadfar, Nosha; Gadalla, Shahinaz; Hashmi, Shahrukh; Hematti, Peiman; Hossain, Nasheed M.; Inamoto, Yoshihiro; Lekakis, Lazaros J.; Sharma, Akshay; Solomon, Scott; Lee, Stephanie J.; Couriel, Daniel R.

doi:10.1016/j.jtct.2023.10.010

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors include human leukocyte antigen (HLA) mismatch, female donors for male recipients, and total body irradiation. Complications post-allo-HSCT involve infections, GVHD, and relapse, with risk assessment relying on clinical characteristics (2,3).…”

Section: Background On Graft-versushost-diseasementioning

confidence: 99%

See 1 more Smart Citation

Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

Iacobescu,

Pop,

Uifălean

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Despite the numerous advantages of allogeneic hematopoietic stem cell transplants (allo-HSCT), there exists a notable association with risks, particularly during the preconditioning period and predominantly post-intervention, exemplified by the occurrence of graft-versus-host disease (GVHD). Risk stratification prior to symptom manifestation, along with precise diagnosis and prognosis, relies heavily on clinical features. A critical imperative is the development of tools capable of early identification and effective management of patients undergoing allo-HSCT. A promising avenue in this pursuit is the utilization of proteomics-based biomarkers obtained from non-invasive biospecimens. This review comprehensively outlines the application of proteomics and proteomics-based biomarkers in GVHD patients. It delves into both single protein markers and protein panels, offering insights into their relevance in acute and chronic GVHD. Furthermore, the review provides a detailed examination of the site-specific involvement of GVHD. In summary, this article explores the potential of proteomics as a tool for timely and accurate intervention in the context of GVHD following allo-HSCT.

show abstract

Section: Background On Graft-versushost-diseasementioning

confidence: 99%

“…The need for risk stratification for GVHD is high, due to problems associated with immunosuppression. It is either not aggressive enough leaving patients with a high GVHD risk vulnerable, or it is too aggressive leading to infections and other complications (3,8).…”

Section: Background On Graft-versushost-diseasementioning

confidence: 99%

Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

Iacobescu,

Pop,

Uifălean

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Improving Outcomes in Allogeneic Transplantation and Chronic Graft-versus-Host Disease Patients through Lifestyle Medicine: Current Landscape and Future Directions

Zhao,

Holtzman,

Golubic

et al. 2024

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Chronic Graft-versus-host Disease: Immune Insights, Therapeutic Advances, and Parallels for Solid Organ Transplantation

Boiko,

Hill

2024

Transplantation

View full text Add to dashboard Cite

Chronic graft-versus-host disease remains a frequent and morbid outcome of allogeneic hematopoietic cell transplantation, in which the donor-derived immune system attacks healthy recipient tissue. Preceding tissue damage mediated by chemoradiotherapy and alloreactive T cells compromise central and peripheral tolerance mechanisms, leading to aberrant donor T cell and germinal center B cell differentiation, culminating in pathogenic macrophage infiltration and differentiation in a target tissue, with ensuant fibrosis. This process results in a heterogeneous clinical syndrome with significant morbidity and mortality, frequently requiring prolonged therapy. In this review, we discuss the processes that interrupt immune tolerance, the subsequent clinical manifestations, and new Food and Drug Administration–approved therapeutic approaches that have been born from a greater understanding of disease pathogenesis in preclinical systems, linking to parallel processes following solid organ transplantation.

show abstract

Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Cited by 5 publications

References 33 publications

Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

Improving Outcomes in Allogeneic Transplantation and Chronic Graft-versus-Host Disease Patients through Lifestyle Medicine: Current Landscape and Future Directions

Chronic Graft-versus-host Disease: Immune Insights, Therapeutic Advances, and Parallels for Solid Organ Transplantation

Contact Info

Product

Resources

About